Blood pressure, calcium channel blockers, and the risk of prostate cancer:: a Mendelian randomization study

Nabila Kazmi; Elena V. Valeeva; Gulshat R. Khasanova; Sarah J Lewis; Denis Plotnikov

doi:10.1007/s10552-023-01712-z

Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study

Nabila Kazmi, Elena V. Valeeva, Gulshat R. Khasanova, Sarah J Lewis, Denis Plotnikov^*

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

4 Citations (Scopus)

36 Downloads (Pure)

Abstract

Background Observational studies have found some evidence of an association between elevated blood pressure and pros-tate cancer risk; however, the results are inconclusive. We tested whether systolic blood pressure (SBP) influences prostate cancer risk and evaluated the effect of calcium channel blockers (CCB) on the disease using Mendelian randomization (MR) approach.Methods We used 278 genetic variants associated with SBP and 16 genetic variants in CCB genes as instrumental variables. Effect estimates were obtained from the UK Biobank sample of 142,995 males and from PRACTICAL consortium (79,148 cases and 61,106 controls).Results For each 10mm Hg increase in SBP the estimated effect was OR 0.96 (0.90–1.01) for overall prostate cancer; and OR 0.92 (0.85–0.99) for aggressive prostate cancer. The MR-estimated effect of a 10mm Hg- SBP lowering through CCB genetic variants was OR 1.22 (1.06–1.42) for all prostate cancers and OR 1.49 (1.18–1.89) for aggressive prostate cancer.Conclusion The results of our study did not support a causal relationship between SBP and prostate cancer; however, we found weak evidence of a protective effect of high SBP on aggressive prostate cancer and we found that blocking calcium channel receptors may increase prostate cancer risk

Original language	English
Pages (from-to)	725–734
Number of pages	10
Journal	Cancer Causes and Control
Volume	34
Issue number	8
DOIs	https://doi.org/10.1007/s10552-023-01712-z
Publication status	Published - 13 May 2023

Bibliographical note

Funding Information:
NKs salary is funded by a research grant from the World Cancer Research Fund (IIG_FULL_2020_01). SJL is supported by a Cancer Research UK 25 (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme).

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Research Groups and Themes

ICEP

Keywords

Blood pressure
prostate cancer
Mendelian randomization
calcium channel blockers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10552-023-01712-z

Full-text PDF (accepted author manuscript)
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Springer at https://doi.org/10.1007/s10552-023-01712-z. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 395 KB

Handle.net

Persistent link

8074 (C18281/A29019) ICEP2 - Programme Award: Towards improved casual evidence and enhanced prediction of cancer risk and survival
Martin, R. M. (Principal Investigator)
1/10/20 → 30/09/25
Project: Research

Cite this

@article{9ab1711e20ed465fafb0201c599592e7,

title = "Blood pressure, calcium channel blockers, and the risk of prostate cancer:: a Mendelian randomization study",

abstract = "Background Observational studies have found some evidence of an association between elevated blood pressure and pros-tate cancer risk; however, the results are inconclusive. We tested whether systolic blood pressure (SBP) influences prostate cancer risk and evaluated the effect of calcium channel blockers (CCB) on the disease using Mendelian randomization (MR) approach.Methods We used 278 genetic variants associated with SBP and 16 genetic variants in CCB genes as instrumental variables. Effect estimates were obtained from the UK Biobank sample of 142,995 males and from PRACTICAL consortium (79,148 cases and 61,106 controls).Results For each 10mm Hg increase in SBP the estimated effect was OR 0.96 (0.90–1.01) for overall prostate cancer; and OR 0.92 (0.85–0.99) for aggressive prostate cancer. The MR-estimated effect of a 10mm Hg- SBP lowering through CCB genetic variants was OR 1.22 (1.06–1.42) for all prostate cancers and OR 1.49 (1.18–1.89) for aggressive prostate cancer.Conclusion The results of our study did not support a causal relationship between SBP and prostate cancer; however, we found weak evidence of a protective effect of high SBP on aggressive prostate cancer and we found that blocking calcium channel receptors may increase prostate cancer risk",

keywords = "Blood pressure, prostate cancer, Mendelian randomization, calcium channel blockers",

author = "Nabila Kazmi and Valeeva, \{Elena V.\} and Khasanova, \{Gulshat R.\} and Lewis, \{Sarah J\} and Denis Plotnikov",

note = "Funding Information: NKs salary is funded by a research grant from the World Cancer Research Fund (IIG\_FULL\_2020\_01). SJL is supported by a Cancer Research UK 25 (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.",

year = "2023",

month = may,

day = "13",

doi = "10.1007/s10552-023-01712-z",

language = "English",

volume = "34",

pages = "725–734",

journal = "Cancer Causes and Control",

issn = "0957-5243",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "8",

}

TY - JOUR

T1 - Blood pressure, calcium channel blockers, and the risk of prostate cancer:

T2 - a Mendelian randomization study

AU - Kazmi, Nabila

AU - Valeeva, Elena V.

AU - Khasanova, Gulshat R.

AU - Lewis, Sarah J

AU - Plotnikov, Denis

N1 - Funding Information: NKs salary is funded by a research grant from the World Cancer Research Fund (IIG_FULL_2020_01). SJL is supported by a Cancer Research UK 25 (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

PY - 2023/5/13

Y1 - 2023/5/13

N2 - Background Observational studies have found some evidence of an association between elevated blood pressure and pros-tate cancer risk; however, the results are inconclusive. We tested whether systolic blood pressure (SBP) influences prostate cancer risk and evaluated the effect of calcium channel blockers (CCB) on the disease using Mendelian randomization (MR) approach.Methods We used 278 genetic variants associated with SBP and 16 genetic variants in CCB genes as instrumental variables. Effect estimates were obtained from the UK Biobank sample of 142,995 males and from PRACTICAL consortium (79,148 cases and 61,106 controls).Results For each 10mm Hg increase in SBP the estimated effect was OR 0.96 (0.90–1.01) for overall prostate cancer; and OR 0.92 (0.85–0.99) for aggressive prostate cancer. The MR-estimated effect of a 10mm Hg- SBP lowering through CCB genetic variants was OR 1.22 (1.06–1.42) for all prostate cancers and OR 1.49 (1.18–1.89) for aggressive prostate cancer.Conclusion The results of our study did not support a causal relationship between SBP and prostate cancer; however, we found weak evidence of a protective effect of high SBP on aggressive prostate cancer and we found that blocking calcium channel receptors may increase prostate cancer risk

AB - Background Observational studies have found some evidence of an association between elevated blood pressure and pros-tate cancer risk; however, the results are inconclusive. We tested whether systolic blood pressure (SBP) influences prostate cancer risk and evaluated the effect of calcium channel blockers (CCB) on the disease using Mendelian randomization (MR) approach.Methods We used 278 genetic variants associated with SBP and 16 genetic variants in CCB genes as instrumental variables. Effect estimates were obtained from the UK Biobank sample of 142,995 males and from PRACTICAL consortium (79,148 cases and 61,106 controls).Results For each 10mm Hg increase in SBP the estimated effect was OR 0.96 (0.90–1.01) for overall prostate cancer; and OR 0.92 (0.85–0.99) for aggressive prostate cancer. The MR-estimated effect of a 10mm Hg- SBP lowering through CCB genetic variants was OR 1.22 (1.06–1.42) for all prostate cancers and OR 1.49 (1.18–1.89) for aggressive prostate cancer.Conclusion The results of our study did not support a causal relationship between SBP and prostate cancer; however, we found weak evidence of a protective effect of high SBP on aggressive prostate cancer and we found that blocking calcium channel receptors may increase prostate cancer risk

KW - Blood pressure

KW - prostate cancer

KW - Mendelian randomization

KW - calcium channel blockers

U2 - 10.1007/s10552-023-01712-z

DO - 10.1007/s10552-023-01712-z

M3 - Article (Academic Journal)

C2 - 37178364

SN - 0957-5243

VL - 34

SP - 725

EP - 734

JO - Cancer Causes and Control

JF - Cancer Causes and Control

IS - 8

ER -